The Republic of China Venture Capital Association hosted its “Venture Capital Star” event and award night on January 15, 2014, and OBI Pharma, Inc. was selected and given the “Best Investment Award” out of over two-hundred nominations.
This was the association’s first time to host the event, and accepted opened nomination to all excellent venture capital or investment projects in Taiwan. In 2013, a total of four awards were presented: The Best Potential Award, The Best Investment Award, The Most Innovative Award, and The Most Promosing IPO Award. OBI Pharma, Inc. was nominated by SinoPac Holdings and won The Best Investment Award.
The Republic of China Venture Capital Association will continue hosting “Venture Capital Star” event, and allow outstanding companies to share their success stories to the public.
About OBI Pharma
OBI Pharma, Inc. is a Taiwan biopharmaceutical company established in 2002. OBI’s mission is to develop novel therapeutic agents for unmet medical needs, including cancer & infectious diseases. The company’s flagship product is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea. Additional information can be found at www.obipharma.com/en
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s most recent filings with the Taiwan Securities and Exchange Commission.
OBI Pharma, Inc.
+886 (2) 2702-8860